Interviews

Naima T. Joseph, MD, MPH, explains measles risks in pregnancy, atypical presentations, and the narrow window for prophylaxis.

Samantha Pettigrew, MD, explains blood clot risk factors, treatment, and return to play in the wake of the news of Jalen Hurts season-ending diagnosis.

Universal HCV testing in pregnancy, DAA therapy, and earlier infant RNA testing can curb mother-to-child hepatitis C transmission.

Kittai, of Perlmutter Cancer Center, discusses choosing therapies to fit patients’ lives and how mentoring energizes him.

Leon W. Herndon Jr, MD, explains how disease severity, medication adherence, and pressure spikes shape surgical planning.

David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.

Ambient AI and analytics may ease clinical workloads and uncover insights, but safety, validated data, HIPAA compliance, and equity must guide adoption.

Immediate DAA treatment, syringe services, and society advocacy are key to eliminating the hepatitis C virus (HCV) among people who use drugs.

Saema Tahir, MD, says oveporexton targets the root cause of narcolepsy type 1, but adverse effects and access barriers will need close management.

EMR inboxes and insurance peer-to-peer calls are pulling clinicians away from patients, a growing concern reflected across CHEST 2026.

Mark Fendrick, MD, discusses survey findings on deprescribing GLP-1 RAs after weight loss as the CMS GLP-1 Bridge Model nears expiration.

A COPD discharge checklist and navigator improved readmissions without lengthening hospital stays or increasing emergency department revisits.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses staffing and tocilizumab access as barriers to expanding BiTE therapy and the costs of cell therapy.

Most specialty pharmacist interventions were routine refill and adherence touchpoints, with symptom trends driving higher-stakes provider escalations.

Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why IVIG, infection monitoring, and deeper bridging responses matter with myeloma immunotherapy.

Tiara Green of Accessia Health says demand for charitable patient assistance is outpacing donations as inflation and Part D changes strain patients.

Charge nurse–led multidisciplinary rounds caught ICU lines and catheters due for removal that academic teaching rounds often missed, said Pooja Roy, MD.

Limited access to care means safety-net ICUs see advanced disease and poorer outcomes, while bias and social media add new challenges to care.

Pulmonologists play a key role in comprehensive biomarker testing, helping more patients with lung cancer access precise targeted therapies.

Managed care pharmacy leaders will gather at AMCP Nexus 2026 to discuss safe AI adoption, evolving drug pricing policy, and practical solutions.

Recent ENDURANCE data support 2-year lenalidomide maintenance in standard-risk multiple myeloma and individualize when to stop.

OneOncology's Larry Bilbrey explains how to guide practices on AI without endorsing products and why technology gaps outweigh workflow problems.

Experts highlight AI adoption, sustained-release glaucoma therapies, and concerns about Medicare payment and rural access.

COA's Nicolas Ferreyros discusses next steps for PBM reform, funding for supportive cancer services, and a hopeful outlook for community oncology.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses advanced practitioners' reimbursement and how outpatient trispecific antibodies could increase access.

Bhavana Bhatnagar, DO, says payer support for social needs, registries, and survivorship care can help patients access therapy and thrive.

Sagar Lonial, MD, lead investigator of the phase 3 EXCALIBER trial, dissects iberdomide data he presented at IMS 2026 and where mezigdomide fits in.